AR061369A1 - PIRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM - Google Patents

PIRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM

Info

Publication number
AR061369A1
AR061369A1 ARP070102594A ARP070102594A AR061369A1 AR 061369 A1 AR061369 A1 AR 061369A1 AR P070102594 A ARP070102594 A AR P070102594A AR P070102594 A ARP070102594 A AR P070102594A AR 061369 A1 AR061369 A1 AR 061369A1
Authority
AR
Argentina
Prior art keywords
alkyl
heterocyclyl
alkynyl
alkenyl
independently selected
Prior art date
Application number
ARP070102594A
Other languages
Spanish (es)
Original Assignee
Astex Therapeutics Ltd
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38831992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR061369(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astex Therapeutics Ltd, Astrazeneca Ab filed Critical Astex Therapeutics Ltd
Publication of AR061369A1 publication Critical patent/AR061369A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Estos compuestos proporcionan un tratamiento o profilaxis para el deterioro cognitivo, la enfermedad de Alzheimer, la neurodegeneracion y la demencia. Reivindicacion 1: Un compuesto de formula 1: donde A se selecciona independientemente entre un anillo heterocíclico de 5, 6 o 7 miembros opcionalmente sustituido con uno o más R1; B se selecciona independientemente entre fenilo o entre un anillo heteroaromático de 5 o 6 miembros opcionalmente sustituido con uno o más R2, C se selecciona independientemente entre fenilo o un anillo heteroaromático de 5 o 6 miembros opcionalmente sustituido con uno o más R3; R1 se selecciona independientemente entre halogeno, ciano, nitro, OR6, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilC0- 6arilo, alquilC0-6heteroarilo, alquilC0-6-cicloalquilo C3-6, alquil C0-6-cicloalquenilo C3-6, alquil C0-6-cicloalquinilo C3-6, alquil C0-6-heterociclilo C3-6, NR6R7, CONR6R7, NR6(CO)R7, O(CO)R6, CO2R6, COR6, (SO2)NR6R7, NR6(SO2)R7, SOR6, SO2R6, OSO2R6 y SO3R6 donde dicho alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilC0-6arilo, alquilC0-6heteroarilo, alquil C0-6-cicloalquilo C3-6, alquil C0-6-cicloalquenilo C3-6, alquil C0-6-cicloalquinilo C3-6 y alquil C0-6 heterociclilo C3-6 está opcionalmente sustituido con uno o más E; o dos sustituyentes R1 junto con el átomo al cual están unidos, forman un anillo cíclico o heterocíclico opcionalmente sustituido con uno o más E; R2, R3 o R4 se selecciona entre arilo, heteroarilo, cicloalquenilo C3-6, cicloalquinilo C3-6, heterociclilo C3-6, CONR6R7, NR6(CO)R7, O(CO)R6, CO2R6, COR6, (SO2)NR6R7, NR6(SO2)R7, SOR6, SO2R6, OSO2R6 y SO3R6 donde dicho arilo, heteroarilo, cicloalquenilo C3-6, cicloalquinilo C3-6 y heterociclilo C3-6 puede estar opcionalmente sustituido con uno o más E; R5se selecciona independientemente entre hidrogeno, ciano, OR6, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilC0-6arilo, alquilC0-6heteroarilo, alquil C0-6-cicloalquilo C3-6, alquil C0-6- cicloalquenilo C3-6, alquil C0-6-cicloalquinilo C3-6, alquiI C0-6heterociclilo C3-6, CONR6R7, CO2R6, COR6, SO2R6 y SO3R6 donde dicho alquiIo C1-6, alquenilo C2-6, aIquinilo C2-6, alquilC0-6arilo, alquilC0-6heteroarilo, alquil C0-6-cicloalquilo C3-6, alquiI C0-6-cicloalquenilo C3-6, alquil C0-6-cicloalquinilo C3-6, alquil C0-6-heterociclilo C3-6 puede estar opcionalmente sustituido con uno o más E; E se selecciona independientemente entre halogeno, nitro, CN, OR6, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilC0-6arilo, alquilC0-6heteroarilo, alquil C0-6-cicloalquilo C3-6, alquil C0-6-cicloalquenilo C3-6, alquil C0-6-cicloalquinilo C3-6, alquil C0-6-heterociclilo, fluormetilo, difluormetilo, trifluormetilo, fluorrnetoxi, difluormetoxi, trifluormetoxi, NR6R7, CONR6R7, NR6(CO)R7, O(CO)R6, CO2R6, COR6, (SO2)NR6R7, NR6SO2R7, SO2R6, SOR6, OSO2R6 y SO3R6, donde dicho alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilC0-6arilo, alquilC0-6heteroarilo, alquil C0-6- cicloalquilo C3-6, alquil C0-6-cicloalquenilo C3-6, alquil C0-6-cicloalquinilo C3-6 o alquilC0-6heterociclilo puede estar opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente entre halo, nitro, ciano, OR6, alquiIo C1- 6, fluormetilo, difluormetilo, trifluormetilo, fluormetoxi, difluormetoxi y trifluormetoxi; R6 y R7 se seleccionan independientemente entre hidrogeno, alquilo C1-6, fluormetilo, difluormetilo, trifluormetilo, alquenilo C2-6, alquinilo C2-6, alquilC0- 6arilo, alquilC0-6heteroarilo, alquil C0-6-cicloalquilo C3-6, alquil C0-6cicloalquenilo C3-6, aIquil C0-6-cicloalquinilo C3-6, alquilC0-6heterociclilo, o R6 y R7 pueden formar en forma conjunta un anillo heterocíclico de 5 o 6 miembros que contiene uno o más heteroátomos seleccionados entre N, O o S; R8 se selecciona independientemente entre halogeno, ciano, nitro, OR9, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilC0-6arilo, alquilC0-6heteroarilo, alquil C0-6-cicloalquilo C3-6, alquil C0-6-cicloalquenilo C3-6, alquil C0-6-cicloalquinilo C3-6, alquil C0-6-heterociclilo C3-6, NR9R10, CONR9R10, NR9(CO)R10, O(CO)R9, CO2R9, COR9, (SO2)NR9R10, NR9(SO2)R10, SO2R9, SOR9, OSO2R9 y SO3R9 donde dicho alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilC0-6arilo, alquilC0-6heteroarilo, alquil C0-6-cicloalquilo C3-6, alquil C0-6-cicloalquenilo C3-6, alquil C0-6-cicloalquinilo C3-6 y alquil C0-6-heterociclilo C3-6 pueden estar opcionalmente sustituidos con uno o más E; o dos R8 pueden junto con los átomos a los cuales están unidos formar un anillo cíclico o heterocíclico opcionalmente sustituido con uno o más E; R9 y R10 se seleccionan independientemente entre hidrogeno, alquilo C1-6, fluormetilo, difluormetilo, trifluormetilo, alquenilo C2-6, alquinilo C2-6, alquilC0-6arilo, alquilC0-6heteroarilo, alquil C0-6-cicloalquilo C3-6, alquil C0-6-cicloalquenilo C3-6, alquil C0-6-cicloalquinilo C3-6, alquilC0-6heterociclilo; o R9 y R10 pueden formar en forma conjunta un anillo heterocíclico de 5 o 6 miembros que contiene uno o más heteroátomos seleccionados entre N, O o S; m= 0,1 o 2; n= 0,1, 2 o 3 p= 0,1, 2 o 3; q= 0,1, 2 o 3; t= 0, 1, 2 o 3; donde uno de n, p o q es por lo menos 1; como una base libre o una sal, solvato o solvato de una sal del mismo aceptable para uso farmacéutico.These compounds provide a treatment or prophylaxis for cognitive impairment, Alzheimer's disease, neurodegeneration and dementia. Claim 1: A compound of formula 1: wherein A is independently selected from a 5-, 6- or 7-membered heterocyclic ring optionally substituted with one or more R1; B is independently selected from phenyl or from a 5- or 6-membered heteroaromatic ring optionally substituted with one or more R2, C is independently selected from phenyl or a 5 or 6-membered heteroaromatic ring optionally substituted with one or more R3; R1 is independently selected from halogen, cyano, nitro, OR6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C0-6alkyl, C0-6 alkyl heteroaryl, C0-6 alkylC3-6 alkyl, C0-6 alkyl C3-6 cycloalkenyl, C0-6 alkyl C3-6 cycloalkynyl, C0-6 alkyl heterocyclyl C3-6, NR6R7, CONR6R7, NR6 (CO) R7, O (CO) R6, CO2R6, COR6, (SO2) NR6R7, NR6 (SO2) R7, SOR6, SO2R6, OSO2R6 and SO3R6 wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C0-6alkyl, C0-6heteroaryl, C0-6-C3-6 alkyl, C0 alkyl -6-C3-6 cycloalkenyl, C0-6 alkyl C3-6 alkyl and C0-6 alkyl C3-6 heterocyclyl optionally is substituted with one or more E; or two R1 substituents together with the atom to which they are attached, form a cyclic or heterocyclic ring optionally substituted with one or more E; R2, R3 or R4 is selected from aryl, heteroaryl, C3-6 cycloalkenyl, C3-6 cycloalkynyl, C3-6 heterocyclyl, CONR6R7, NR6 (CO) R7, O (CO) R6, CO2R6, COR6, (SO2) NR6R7, NR6 (SO2) R7, SOR6, SO2R6, OSO2R6 and SO3R6 wherein said aryl, heteroaryl, C3-6 cycloalkenyl, C3-6 cycloalkynyl and C3-6 heterocyclyl may be optionally substituted with one or more E; R5 is independently selected from hydrogen, cyano, OR6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C0-6 alkyl, C0-6heteroaryl, C0-6 alkylC3-6 alkyl, C0-6-cycloalkenyl alkyl -6, C0-6 alkyl C3-6 alkyl, C0-6 alkyl C3-6 heterocyclyl, CONR6R7, CO2R6, COR6, SO2R6 and SO3R6 wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C0-6 alkyl , C0-6 alkyl heteroaryl, C0-6 alkyl C3-6 alkyl, C0-6 alkyl C3-6 alkyl, C0-6 alkyl C3-6 cycloalkynyl, C0-6 alkyl C3-6 heterocyclyl may be optionally substituted with one or more E; E is independently selected from halogen, nitro, CN, OR6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C0-6 alkyl, C0-6 alkyl heteroaryl, C0-6 alkylC3-6 alkyl, C0-6 alkyl C3-6cycloalkenyl, C0-6 alkyl C3-6 alkyl, C0-6 alkyl heterocyclyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluorrnethoxy, difluoromethoxy, trifluoromethoxy, NR6R7, CONR6R7, NR6 (CO) R7, O (CO) R7, O (CO) R7, O (CO) R7, O (CO) R7 , CO2R6, COR6, (SO2) NR6R7, NR6SO2R7, SO2R6, SOR6, OSO2R6 and SO3R6, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C0-6aryl, C0-6henylaryl, C0-6- alkyl C3-6 cycloalkyl, C0-6 alkyl C3-6 cycloalkenyl, C0-6 alkyl C3-6 cycloalkynyl or C0-6 alkyl heterocyclyl may be optionally substituted with one or more substituents independently selected from halo, nitro, cyano, OR6, C1 alkyl - 6, fluormethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy and trifluoromethoxy; R6 and R7 are independently selected from hydrogen, C1-6 alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, C2-6 alkenyl, C2-6 alkynyl, C0-6aryl alkyl, C0-6heteroaryl alkyl, C0-6 alkylC3-6 alkyl, C0 alkyl -6 C3-6cycloalkenyl, C0-6 alkyl-C3-6 cycloalkynyl, C0-6 alkyl heterocyclyl, or R6 and R7 can together form a 5 or 6 membered heterocyclic ring containing one or more heteroatoms selected from N, O or S ; R8 is independently selected from halogen, cyano, nitro, OR9, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C0-6 alkyl, C0-6 alkyl heteroaryl, C0-6 alkylC3-6 alkyl, C0-6 alkyl C3-6cycloalkenyl, C0-6 alkyl C3-6 alkyl, C0-6 alkyl heterocyclyl C3-6, NR9R10, CONR9R10, NR9 (CO) R10, O (CO) R9, CO2R9, COR9, (SO2) NR9R10 , NR9 (SO2) R10, SO2R9, SOR9, OSO2R9 and SO3R9 wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C0-6alkyl, C0-6heteroaryl, C0-6-C3-6 alkyl alkyl, alkyl C0-6-C3-6 cycloalkenyl, C0-6 alkyl C3-6 alkyl and C0-6 alkyl C3-6 heterocyclyl may be optionally substituted with one or more E; or two R8 may together with the atoms to which they are attached form a cyclic or heterocyclic ring optionally substituted with one or more E; R9 and R10 are independently selected from hydrogen, C1-6 alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, C2-6 alkenyl, C2-6 alkynyl, C0-6 alkyl, C0-6 alkyl, C0-6 alkyl, C0-6 alkyl, C0 alkyl -6-C3-6 cycloalkenyl, C0-6 alkyl-C3-6 cycloalkynyl, C0-6 alkyl heterocyclyl; or R9 and R10 may together form a 5- or 6-membered heterocyclic ring containing one or more heteroatoms selected from N, O or S; m = 0.1 or 2; n = 0.1, 2 or 3 p = 0.1, 2 or 3; q = 0.1, 2 or 3; t = 0, 1, 2 or 3; where one of n, p or q is at least 1; as a free base or a salt, solvate or solvate of a salt thereof acceptable for pharmaceutical use.

ARP070102594A 2006-06-14 2007-06-13 PIRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM AR061369A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81372806P 2006-06-14 2006-06-14
US89699407P 2007-03-26 2007-03-26

Publications (1)

Publication Number Publication Date
AR061369A1 true AR061369A1 (en) 2008-08-20

Family

ID=38831992

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102594A AR061369A1 (en) 2006-06-14 2007-06-13 PIRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM

Country Status (7)

Country Link
EP (1) EP2035423A1 (en)
JP (1) JP2009539973A (en)
AR (1) AR061369A1 (en)
CL (1) CL2007001733A1 (en)
TW (1) TW200815443A (en)
UY (1) UY30407A1 (en)
WO (1) WO2007145568A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
JP2008508289A (en) 2004-07-28 2008-03-21 シェーリング コーポレイション Macrocyclic β-secretase inhibitor
KR20080028881A (en) 2005-06-14 2008-04-02 쉐링 코포레이션 Heterocyclic aspartyl protease inhibitors, preparation and use thereof
CA2609582A1 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
WO2008063114A1 (en) * 2006-11-20 2008-05-29 Astrazeneca Ab Amino- imidazolones and their use as medicament for treating cognitive impairment alzheimer disease, neurodegeneration and dementia
CA2721738A1 (en) 2008-04-22 2009-10-29 Schering Corporation Thiophenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
US8563543B2 (en) 2009-10-08 2013-10-22 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2011044185A2 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
UA108363C2 (en) 2009-10-08 2015-04-27 IMINOTIADIASIADIOXIDE OXIDES AS BACE INHIBITORS, COMPOSITIONS THEREOF AND THEIR APPLICATIONS
WO2011044184A1 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
HUE026338T2 (en) * 2011-03-01 2016-05-30 Janssen Pharmaceutica Nv 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace)
WO2012138590A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
BR112014004181A2 (en) 2011-08-22 2017-06-13 Merck Sharp & Dohme compound, pharmaceutical composition, and method of treating, preventing, and / or delaying the onset of a disease or condition
JP6482458B2 (en) 2012-03-19 2019-03-13 バック・インスティテュート・フォー・リサーチ・オン・エイジング APP-specific BACE (ASBI) and uses thereof
EP2908825B1 (en) 2012-10-17 2018-04-18 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2908824B1 (en) 2012-10-17 2018-05-02 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US20140371283A1 (en) 2013-02-12 2014-12-18 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
JP7419865B2 (en) 2020-02-17 2024-01-23 東ソー株式会社 Aromatic halogen compounds, their uses, and manufacturing methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2578600A1 (en) * 2004-06-16 2006-01-26 Wyeth Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase
WO2006076284A2 (en) * 2005-01-14 2006-07-20 Wyeth AMINO-IMIDAZOLONES FOR THE INHIBITION OF ß-SECRETASE

Also Published As

Publication number Publication date
EP2035423A1 (en) 2009-03-18
WO2007145568A1 (en) 2007-12-21
JP2009539973A (en) 2009-11-19
WO2007145568A9 (en) 2008-12-11
TW200815443A (en) 2008-04-01
CL2007001733A1 (en) 2008-01-25
UY30407A1 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
AR061369A1 (en) PIRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM
AR061371A1 (en) AMINO - IMIDAZOLONAS AND ITS USE AS A MEDICINAL PRODUCT FOR ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES.
AR061372A1 (en) AMINO-IMIDAZOLES AND ITS USES AS MEDICINES FOR THE TREATMENT OF ALZHEIMER EVIL, DEMENTIA AND NEURODEGENERATION
AR061370A1 (en) IMIDAZOPIRIMIDINE DERIVATIVES
AR066562A1 (en) CONDENSED PIRROL DERIVATIVES; A PHARMACEUTICAL FORMULATION BASED ON THE COMPOUND AND ITS USE TO PREPARE MEDICINES
AR061564A1 (en) DERIVATIVES OF ISOINDOLS, PHARMACEUTICAL COMPOSITIONS AND USES
ECSP088149A (en) 3-ACILAMINOBENZANILIDAS INSECTICIDAS
ES2530943T3 (en) Chromenone derivatives with antitumor activity
AR088449A1 (en) BENZILINDAZOLES REPLACED
PE20130155A1 (en) ARYLETINYL DERIVATIVES
ES2590504T3 (en) N-cyclolamides as nematicides
AR062677A1 (en) DERIVATIVES OF BIARIL-SULFONAMIDE, PRODUCTION PROCESSES AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM
AR066561A1 (en) IMIDAZOL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES
AR075854A1 (en) BETA-SECRETASA INHIBITORS
AR054560A1 (en) SPIROPIPERIDINE AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
AR096979A1 (en) DERIVATIVES OF PIRROL, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR061739A1 (en) NEW NAFTALENIC DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR082886A1 (en) COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR055878A1 (en) CYCLOPROPANOCARBOXAMIDE DERIVATIVES
AR052568A1 (en) DERIVATIVES OF PIRAZOLO-PYRIMIDINE AS ANGLOSTS OF MGLUR2
CO6220949A2 (en) PIRAZOLIC DERIVATIVES AS INHIBITORS OF THE 11 BETA -HSD1
ECSP109958A (en) PIRIMIDINE DERIVATIVES 934
AR071323A1 (en) HETEROCICLIC DERIVATIVES OF GLUCOQUINASE ACTIVATING PYRIDAZINONES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, METHOD OF PREPARATION AND USE OF THE SAME IN THE TREATMENT OF MELLITUS TYPE II DIABETES.
AR067613A1 (en) PK-DNA INHIBITORS, USE AND SYNTHESIS OF THE SAME
AR068115A1 (en) DERIVED FROM PIRAZOLCARBOXILICO ACID PRODUCTION METHOD OF THE SAME AND FUNGICIDE

Legal Events

Date Code Title Description
FB Suspension of granting procedure